Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke

血液转录组学作为 CT 佐剂排除急性中风出血

基本信息

  • 批准号:
    10611988
  • 负责人:
  • 金额:
    $ 56.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-15 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

What? We will test the accuracy of an RNA-seq based biomarker assay to predict the diagnosis of stroke in a minority population (African American). We will investigate the impact of sex and race on test accuracy, and investigate novel sequencing approaches to speed up the time to obtain actionable results (Nanopores). Why? When using the thrombolytic tPA, time is of the essence, as the drug must be administered within 3-4.5 hrs of stroke onset. The sooner with in this time window that tPA can be administered, the greater the benefit. In addition, intracerebral hemorrhage must have been excluded by CT scanning; currently the sole method to make this therapeutically critical determination. Delays in radiologist interpretation of CT results, or lack of available imaging facilities is the most common reason for thrombolytic treatment not being initiated. . Thus corroborative use of a highly sensitive blood test would permit ER physicians to be confident of their CT interpretation in settings without onsite CT reading by a radiologist. Timely administration of tPA would thereby be permitted reducing stroke burden. Accordingly, a rapid biomarker test to exclude hemorrhage in acute stroke would reduce door to needle times, lower mortality, and improve outcome in stroke. Stroke burden is higher in African Americans and females, yet these populations have lower representation in genomic research. We test the impact of sex and race by assessing test accuracy derived from a single sex or race, and then tested in the opposite sex, or Caucasians. These experiments will determine whether mixed sex or race derived tests are more accurate than those derived from a single population. Finally, we investigate approaches to speed up testing using novel Nanopore sequencing technology. How? Our studies of blood biomarkers, developed at Grady Memorial Hospital Marcus Stroke Center, offers a diagnostic blood test that discriminates between ischemic and hemorrhagic stroke. We do not rely on single biomarkers but rather use analysis of the entire transcriptome (all RNA) in venous blood, by the use of next generation RNA sequencing. These data provide highly accurate stroke diagnosis, determine stroke subtype, offer powerful prediction of outcome, and show differences and treatment response by sex. We hypothesize transcriptome differences in peripheral blood can predict CT diagnosis of hemorrhagic vs. ischemic stroke. We propose to recruit patients from the Grady memorial hospital, and obtain blood samples for RNA sequencing. From this dataset we will test three specific aims: AIM ONE: Determine the accuracy of blood RNA profiles to predict CT documented hemorrhagic stroke. AIM TWO: Determine the effect of sex and race on transcriptomic profile accuracy. AIM THREE: Show the accuracy of rapid RNA measurement techniques to identify ischemic brain hemorrhage profiles. IMPACT: A rapid point of care blood test to diagnosis stroke and stroke subtype will increase the percentage of the acute stroke population eligible for tPA therapy, significantly reducing stroke morbidity and mortality.
- 你说什么?我们将测试基于RNA-seq的生物标志物测定的准确性,以预测中风的诊断, 少数民族(非裔美国人)。我们将调查性别和种族对测试准确性的影响, 研究新的测序方法,以加快获得可操作结果的时间(纳米孔)。 为什么?为什么?当使用溶栓tPA时,时间是关键,因为药物必须在3-4.5分钟内施用。 中风发作的小时数。在这个时间窗内,tPA可以施用得越早,益处越大。 此外,必须通过CT扫描排除脑出血;目前唯一的方法, 做出这个治疗上的决定放射科医生对CT结果的解释延迟,或缺乏 可用的成像设备是未开始溶栓治疗的最常见原因。.因此 高灵敏度血液检查的确证性使用将使急诊室医生对他们的CT有信心 在没有放射科医师现场CT阅读的情况下进行解释。及时给予tPA, 允许减少中风负担。因此,快速生物标志物测试以排除急性脑出血, 中风将减少门到针的时间,降低死亡率,并改善中风的结果。 非裔美国人和女性的卒中负担更高,但这些人群在 基因组研究我们测试性别和种族的影响,通过评估测试的准确性来自单一性别或 种族,然后在异性或高加索人中进行测试。这些实验将决定混合性别 或种族衍生的测试比来自单一群体的测试更准确。最后,我们调查 使用新的纳米孔测序技术加速测试的方法。 怎么做的?我们在格雷迪纪念医院马库斯中风中心开展的血液生物标志物研究,提供了一个 区分缺血性和出血性中风的诊断性血液检查。我们不依赖单一的 生物标志物,而是使用静脉血中的整个转录组(所有RNA)的分析,通过使用下一个 RNA测序。这些数据提供了高度准确的中风诊断,确定中风亚型, 提供强有力的结果预测,并显示性别差异和治疗反应。我们假设 外周血转录组差异可预测出血性与缺血性卒中的CT诊断。我们 建议从格雷迪纪念医院招募病人,并获得血液样本进行RNA测序。 从这个数据集,我们将测试三个具体的目标:目的一:确定血液RNA谱的准确性, 预测CT记录的出血性卒中。目的二:确定性别和种族对转录组学的影响。 轮廓精度。目的三:显示快速RNA测量技术在识别缺血性 脑出血特征 影响:用于诊断卒中和卒中亚型的快速护理点血液检测将增加 适合tPA治疗的急性卒中人群,显著降低卒中发病率和死亡率。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Changes in NMDA Receptor Function in Rapid Ischemic Tolerance: A Potential Role for Tri-Heteromeric NMDA Receptors.
  • DOI:
    10.3390/biom12091214
  • 发表时间:
    2022-09-01
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
  • 通讯作者:
Whole Blood Transcriptome Analysis in Children with Sickle Cell Anemia.
  • DOI:
    10.3389/fgene.2021.737741
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Gee BE;Pearson A;Buchanan-Perry I;Simon RP;Archer DR;Meller R
  • 通讯作者:
    Meller R
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT MELLER其他文献

ROBERT MELLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT MELLER', 18)}}的其他基金

Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
  • 批准号:
    10396630
  • 财政年份:
    2020
  • 资助金额:
    $ 56.08万
  • 项目类别:
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
  • 批准号:
    10210310
  • 财政年份:
    2020
  • 资助金额:
    $ 56.08万
  • 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
  • 批准号:
    8142097
  • 财政年份:
    2008
  • 资助金额:
    $ 56.08万
  • 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
  • 批准号:
    8332845
  • 财政年份:
    2008
  • 资助金额:
    $ 56.08万
  • 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
  • 批准号:
    7915525
  • 财政年份:
    2008
  • 资助金额:
    $ 56.08万
  • 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
  • 批准号:
    7694369
  • 财政年份:
    2008
  • 资助金额:
    $ 56.08万
  • 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
  • 批准号:
    7583695
  • 财政年份:
    2008
  • 资助金额:
    $ 56.08万
  • 项目类别:
Rapid ischemic tolerance: Ubiquitin-mediated structural reorganization
快速缺血耐受:泛素介导的结构重组
  • 批准号:
    7282685
  • 财政年份:
    2006
  • 资助金额:
    $ 56.08万
  • 项目类别:
Rapid ischemic tolerance: Ubiquitin-mediated structural reorganization
快速缺血耐受:泛素介导的结构重组
  • 批准号:
    7149477
  • 财政年份:
    2006
  • 资助金额:
    $ 56.08万
  • 项目类别:
Protein ubiquitination based neuroprotection for stroke
基于蛋白质泛素化的中风神经保护
  • 批准号:
    6862336
  • 财政年份:
    2005
  • 资助金额:
    $ 56.08万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 56.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了